These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 8361761)

  • 1. The v-Rel oncoprotein increases expression from Sp1 site-containing promoters in chicken embryo fibroblasts.
    Sif S; Capobianco AJ; Gilmore TD
    Oncogene; 1993 Sep; 8(9):2501-9. PubMed ID: 8361761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repression of the chicken c-rel promoter by vRel in chicken embryo fibroblasts is not mediated through a consensus NF-kappa B binding site.
    Capobianco AJ; Gilmore TD
    Oncogene; 1991 Dec; 6(12):2203-10. PubMed ID: 1766669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts.
    Morrison LE; Boehmelt G; Enrietto PJ
    Oncogene; 1992 Jun; 7(6):1137-47. PubMed ID: 1594245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
    Mosialos G; Gilmore TD
    Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TATA-box dependent trans-activation of the human HSP70 promoter by Myb proteins.
    Foos G; Natour S; Klempnauer KH
    Oncogene; 1993 Jul; 8(7):1775-82. PubMed ID: 8510924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.
    Sarkar S; Gilmore TD
    Oncogene; 1993 Aug; 8(8):2245-52. PubMed ID: 8336947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. v-rel- and c-rel-protein complexes bind to the NF-kappa B site in vitro.
    Kochel T; Rice NR
    Oncogene; 1992 Mar; 7(3):567-72. PubMed ID: 1549370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
    Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
    Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional activity of rel family proteins.
    McDonnell PC; Kumar S; Rabson AB; Gélinas C
    Oncogene; 1992 Jan; 7(1):163-70. PubMed ID: 1741161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
    Starczynowski DT; Reynolds JG; Gilmore TD
    Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A yeast transcription assay defines distinct rel and dorsal DNA recognition sequences.
    Kamens J; Brent R
    New Biol; 1991 Oct; 3(10):1005-13. PubMed ID: 1768648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The v-rel oncogene encodes a cell-specific transcriptional activator of certain promoters.
    Gélinas C; Temin HM
    Oncogene; 1988 Oct; 3(4):349-55. PubMed ID: 2856247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-MYB transactivates its own promoter through SP1-binding sites.
    Sala A; Saitta B; De Luca P; Cervellera MN; Casella I; Lewis RE; Watson R; Peschle C
    Oncogene; 1999 Feb; 18(6):1333-9. PubMed ID: 10022815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective activation of the proto-oncogene c-jun promoter by the transforming protein v-Rel.
    Fujii M; Minamino T; Nomura M; Miyamoto KI; Tanaka J; Seiki M
    Oncogene; 1996 May; 12(10):2193-202. PubMed ID: 8668346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice.
    Carrasco D; Rizzo CA; Dorfman K; Bravo R
    EMBO J; 1996 Jul; 15(14):3640-50. PubMed ID: 8670867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. rel/NF-kappa B nuclear complexes that bind kB sites in the murine c-rel promoter are required for constitutive c-rel transcription in B-cells.
    Grumont RJ; Richardson IB; Gaff C; Gerondakis S
    Cell Growth Differ; 1993 Sep; 4(9):731-43. PubMed ID: 8241021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two novel functions associated with the Rel oncoproteins: DNA replication and cell-specific transcriptional activation.
    Ishikawa H; Asano M; Kanda T; Kumar S; Gélinas C; Ito Y
    Oncogene; 1993 Nov; 8(11):2889-96. PubMed ID: 8414493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of Ets, rel and Sp1-like proteins in lipopolysaccharide-mediated activation of the HIV-1 LTR in macrophages.
    Sweet MJ; Stacey KJ; Ross IL; Ostrowski MC; Hume DA
    J Inflamm; 1998; 48(2):67-83. PubMed ID: 9656143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transactivation of the GATA-1 promoter by a myb-ets-containing mouse retrovirus is mediated by CACCC elements.
    Sun-Hoffman L; Aurigemma RE; Sun B; Ruscetti SK
    Oncogene; 1996 Sep; 13(5):1037-42. PubMed ID: 8806693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in kappaB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein.
    Nehyba J; Hrdlicková R; Bose HR
    Oncogene; 1997 Jun; 14(24):2881-97. PubMed ID: 9205096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.